FDA shrinks TEA estimate
This article was originally published in The Tan Sheet
Executive Summary
The agency expects to receive annually two time-and-extent applications from firms requesting consideration of ingredients for inclusion in the OTC drug monograph system. As detailed in an Oct. 8 Federal Register 1notice soliciting public comment, the TEA estimate represents a substantial drop from FDA's 2002 TEA final rule, which projected 50 applications per year (2"The Tan Sheet" Jan. 28, 2002). The agency has received only 16 TEAs since 2003. The notice also lowers the annual expectation for safety and effectiveness data submissions for OTC drugs, from 90 to two. FDA will accept comments on its proposed estimates through Dec. 7
You may also be interested in...
OTC “Time & Extent” Requirements Reduced For Extensively Marketed Drugs
Sponsors of OTC drugs with extensive foreign marketing experience need not provide detailed information from each country in requesting the drug or "condition" be considered for OTC monograph eligibility in the U.S., FDA says
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.